As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

Merck's Vaxneuvance – formerly known as V114 – is the first major competition to Pfizer's franchise in the big market for conjugate pneumococcal vaccines ... with its off-label use.

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

This year, pharmaceutical giant Merck (NYSE: MRK ... such as its pair of HPV vaccines, Gardasil and Gardasil 9. Further, the ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

Merck will face an important patent cliff by ... such as its pair of HPV vaccines, Gardasil and Gardasil 9. Further, the company has a deep pipeline, with more than 80 programs in phase 2 studies ...